Key Highlights
- CEO Pascal Soriot acquired 60,000 AstraZeneca shares for £121.02 apiece on September 14, 2026
- European CHMP committee delivered favorable opinion supporting Klygefa (gefurulimab) approval for generalised myasthenia gravis
- Phase III PREVAIL trial demonstrated Klygefa achieved its primary endpoint, with findings featured in JAMA Neurology
- Upon approval, Klygefa will represent the EU’s inaugural dual-binding nanobody C5 inhibitor for this condition
- Global regulatory submissions for Klygefa remain under assessment in the United States, China, and additional territories
In a significant display of confidence, AstraZeneca CEO Pascal Soriot invested more than £7.26 million in his company’s stock, acquiring 60,000 ordinary shares at a price of £121.02 per share on September 14, 2026, through the London Stock Exchange. This transaction was formally reported in accordance with UK market abuse regulations.
Soriot’s substantial share purchase occurred during the same timeframe that AstraZeneca’s rare disease division, Alexion, secured a significant regulatory milestone in Europe.
The Committee for Medicinal Products for Human Use (CHMP), operating under the European Medicines Agency, delivered a favorable assessment supporting the authorization of Klygefa (gefurulimab) throughout the European Union. The proposed indication covers adjunctive treatment for generalised myasthenia gravis (gMG) in adult patients testing positive for anti-acetylcholine receptor (AChR) antibodies.
Generalised myasthenia gravis represents a rare autoimmune condition characterized by significant muscle weakness and impaired muscle performance. Throughout five major European nations—Germany, France, the United Kingdom, Italy, and Spain—approximately 82,500 individuals live with gMG, with roughly 66,000 presenting as AChR-positive.
The CHMP’s favorable assessment drew upon data generated from the Phase III PREVAIL clinical study. These trial findings received publication in the medical journal JAMA Neurology.
In the PREVAIL trial, Klygefa successfully achieved its primary endpoint. The therapy demonstrated statistically significant improvement from baseline measurements in the Myasthenia Gravis Activities of Daily Living score at the 26-week mark compared to placebo. The treatment difference measured -1.6, accompanied by a p-value below 0.0001.
Patient improvement manifested as early as the first week and sustained throughout the complete 26-week study duration.
Groundbreaking Treatment Option
Should the European Commission grant formal authorization following the CHMP recommendation—which represents standard procedure—Klygefa will establish itself as the first dual-binding nanobody C5 inhibitor authorized for this specific patient demographic within the European Union.
The medication is delivered weekly through subcutaneous self-administration utilizing an autoinjector device, providing patients with a practical at-home treatment solution.
Clinical data indicated Klygefa demonstrated generally favorable tolerability. The safety characteristics aligned with previous clinical trials evaluating C5 inhibitors eculizumab and ravulizumab in gMG patient populations.
Global Regulatory Landscape
Klygefa has secured authorization in Japan and multiple additional jurisdictions for specific adult gMG patient groups.
Regulatory applications incorporating PREVAIL study results are presently undergoing evaluation by authorities in the United States and China, alongside other international markets.
AZN stock advanced 0.63% at the time of this report. Current analyst consensus rates AZN as a Buy, establishing a price target of £15,200.
The company maintains a market capitalization of £188.2 billion, accompanied by average daily share volume of approximately 3.3 million.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
